Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash & Equivalents (2020 - 2025)

Oncology Institute (TOI) has disclosed Cash & Equivalents for 6 consecutive years, with $27.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 41.65% year-over-year to $27.7 million, compared with a TTM value of $27.7 million through Sep 2025, down 41.65%, and an annual FY2024 reading of $49.7 million, up 48.32% over the prior year.
  • Cash & Equivalents was $27.7 million for Q3 2025 at Oncology Institute, down from $30.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $115.2 million in Q4 2021 and bottomed at $11.5 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $40.9 million, with a median of $33.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 1820.21% in 2021, then tumbled 87.84% in 2022.
  • Year by year, Cash & Equivalents stood at $115.2 million in 2021, then crashed by 87.84% to $14.0 million in 2022, then skyrocketed by 139.03% to $33.5 million in 2023, then soared by 48.32% to $49.7 million in 2024, then plummeted by 44.32% to $27.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for TOI at $27.7 million in Q3 2025, $30.3 million in Q2 2025, and $39.7 million in Q1 2025.